Institutional members access full text with Ovid®

Share this article on:

Metastastic Choriocarcinoma in a Term Pregnancy: A Case Study

Hensley, Jennifer G. EdD, CNM, WHNP; Shviraga, Bonita A. PhD, CNM

MCN: The American Journal of Maternal/Child Nursing: January/February 2014 - Volume 39 - Issue 1 - p 8–15
doi: 10.1097/NMC.0b013e3182a8de5b
Feature: CE Connection

The focus of this article is choriocarcinoma (CC), a rare and aggressive obstetric/gynecologic cancer that occurs once in every 20,000 to 40,000 pregnancies. CC is a form of gestational trophoblastic disease, which is the result of abnormal trophoblastic activity encompassing a spectrum of nonmalignant and malignant disease. Forms of gestational trophoblastic disease include complete or partial mole, invasive mole, CC, placental site trophoblastic tumor, and epithelioid trophoblastic tumor.

Typically asymptomatic, the first symptom of CC in 80% of cases is shortness of breath, indicative of metastasis to the lungs. CC affects women of all ages and can occur during pregnancy, after birth, or even years remote from the antecedent pregnancy. It is highly responsive to chemotherapy, with an overall remission rate greater than 90%. This case study presents the story of a pregnant adolescent thought to have an uneventful pregnancy until metastatic CC at term was diagnosed. Available treatments, outcomes and surveillance for the disease, psychosocial aspects, and implications for nursing care are discussed.

This case study will provide you with important information about how to care for a woman who has this most difficult of complications.

Jennifer G. Hensley is an assistant professor at the University of Colorado Denver, Aurora, CO. She can be reached via e-mail at

Bonita A. Shviraga is a clinical manager at the Aurora Nurse-Midwives, Aurora, CO.

For more than 150 additional continuing nursing education articles on maternal/child topics, go to

The authors have disclosed there are no financial relationships related to this article.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.